Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

China Pharma Holdings (CPHI) Accumulated Depreciation & Amortization (2016 - 2025)

China Pharma Holdings' Accumulated Depreciation & Amortization history spans 16 years, with the latest figure at $33.5 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 4.33% year-over-year to $33.5 million; the TTM value through Dec 2025 reached $33.5 million, up 4.33%, while the annual FY2025 figure was $33.5 million, 4.33% up from the prior year.
  • Accumulated Depreciation & Amortization reached $33.5 million in Q4 2025 per CPHI's latest filing, up from $33.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $33.5 million in Q4 2025 to a low of $26.1 million in Q2 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $30.0 million, with a median of $29.4 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: grew 22.77% in 2021, then grew 0.68% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $28.2 million in 2021, then increased by 0.68% to $28.4 million in 2022, then grew by 7.21% to $30.4 million in 2023, then grew by 5.61% to $32.1 million in 2024, then increased by 4.33% to $33.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Accumulated Depreciation & Amortization are $33.5 million (Q4 2025), $33.0 million (Q3 2025), and $32.6 million (Q2 2025).